WO2005027845A3 - Method of identifying cell surface molecules involved in cancer metastasis - Google Patents

Method of identifying cell surface molecules involved in cancer metastasis Download PDF

Info

Publication number
WO2005027845A3
WO2005027845A3 PCT/US2004/030555 US2004030555W WO2005027845A3 WO 2005027845 A3 WO2005027845 A3 WO 2005027845A3 US 2004030555 W US2004030555 W US 2004030555W WO 2005027845 A3 WO2005027845 A3 WO 2005027845A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell surface
cancer metastasis
surface molecules
molecules involved
identifying cell
Prior art date
Application number
PCT/US2004/030555
Other languages
French (fr)
Other versions
WO2005027845A2 (en
Inventor
Katherine S Bowdish
Anke Kretz-Rommel
Original Assignee
Alexion Pharma Inc
Katherine S Bowdish
Anke Kretz-Rommel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Katherine S Bowdish, Anke Kretz-Rommel filed Critical Alexion Pharma Inc
Publication of WO2005027845A2 publication Critical patent/WO2005027845A2/en
Publication of WO2005027845A3 publication Critical patent/WO2005027845A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for identifying antibodies to cell surafce molecules common to cells which migrate through the human lymph system which utilize alternating panning on two different types of cells known to migrate through the human lymph system.
PCT/US2004/030555 2003-09-18 2004-09-18 Method of identifying cell surface molecules involved in cancer metastasis WO2005027845A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50377003P 2003-09-18 2003-09-18
US60/503,770 2003-09-18

Publications (2)

Publication Number Publication Date
WO2005027845A2 WO2005027845A2 (en) 2005-03-31
WO2005027845A3 true WO2005027845A3 (en) 2006-03-02

Family

ID=34375397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030555 WO2005027845A2 (en) 2003-09-18 2004-09-18 Method of identifying cell surface molecules involved in cancer metastasis

Country Status (1)

Country Link
WO (1) WO2005027845A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US6277972B1 (en) * 1998-08-10 2001-08-21 Urogenesys, Inc. BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US6277972B1 (en) * 1998-08-10 2001-08-21 Urogenesys, Inc. BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products

Also Published As

Publication number Publication date
WO2005027845A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
WO2009048530A3 (en) Highly multiplexed particle-based assays
EP1585966A3 (en) METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
SG10201808491UA (en) Methods, kits and apparatus for expanding a population of cells
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
UA94576C2 (en) Isolated antibody that binds to igf-1r, composition and methods relating to anti-igf-1 receptor antibodies
WO2003086174A3 (en) A new method for the diagnosis and prognosis of malignant diseases
TW200801039A (en) Separation methods
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
MX2009013655A (en) Mass spectrometry method for measuring vitamin b6 in body fluid.
EP1833968A4 (en) Cancer specific antibody and cell surface proteins
WO2003060474A3 (en) Microscale electrophoresis devices for biomolecule separation and detection
AU2003250506A8 (en) Method for the characteristation of nucleic acid molecules
WO2007117763A3 (en) Methods and compositions for targeting relt
EP1685236A4 (en) Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
EP1685379A4 (en) Methods for identifying cell surface receptor protein modulators
WO2005028621A3 (en) Assays with primary cells
WO2005027845A3 (en) Method of identifying cell surface molecules involved in cancer metastasis
WO2006031831A3 (en) Methods for the detection of ovarian cancer
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
AU2001280368A1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase